Nanodiagnostika - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 394,945 | 459,351 | 467,298 | 808,139 | 687,949 | 678,294 | 813,622 | 988,607 |
| Profit before tax | 33,288 | 74,632 | 27,153 | 278,175 | 114,079 | 38,719 | 41,314 | 63,327 |
| Net profit | 28,212 | 74,632 | 27,153 | 275,035 | 114,079 | 38,719 | 39,425 | 60,780 |
| Equity | 137,352 | 164,926 | 142,668 | 318,879 | 350,606 | 271,678 | 193,456 | 148,346 |
| Liabilities | 95,476 | 180,977 | 137,828 | 119,533 | 113,188 | 92,590 | 57,436 | 83,122 |
| Non-current assets | 62,130 | 178,493 | 49,157 | 141,208 | 83,529 | 101,397 | 77,677 | 73,026 |
| Current assets | 159,416 | 166,119 | 230,031 | 295,247 | 378,325 | 259,559 | 170,094 | 155,263 |
| Total assets | 221,546 | 344,612 | 279,188 | 436,455 | 461,854 | 360,956 | 247,771 | 228,289 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 109,529 | 126,146 | 182,097 |
| Social insurance contributions | - | - | - | - | - | 28,802 | 2,723 | 2,247 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +3.9% | +16.3% | +1.7% | +72.9% | -14.9% | -1.4% | +20.0% | +21.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 12.7% | 21.7% | 9.7% | 63.0% | 24.7% | 10.7% | 15.9% | 26.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 20.5% | 45.3% | 19.0% | 86.3% | 32.5% | 14.3% | 20.4% | 41.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 7.1% | 16.2% | 5.8% | 34.0% | 16.6% | 5.7% | 4.8% | 6.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 8.4% | 16.2% | 5.8% | 34.4% | 16.6% | 5.7% | 5.1% | 6.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.7 | 1.1 | 1.0 | 0.4 | 0.3 | 0.3 | 0.3 | 0.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 197,473 | 54,576 | 53,919 | 103,167 | 71,167 | 84,787 | 250,345 | 237,264 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Nanodiagnostika - Social security debts
The company had no debts to Sodra
Nanodiagnostika - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-08-05 | 2026-08-17 | 297.73 |
| 2026-07-03 | 2026-07-07 | 32.8 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Nanodiagnostika, UAB (code 302477512) is a Private Limited Liability Company operating in wholesale of pharmaceutical and medical goods. In 2025, revenue increased to €988.6K, up 21.5% year on year and 45.8% over two years, showing sustained top-line expansion. Net profit also improved to €60.8K, compared with €39.4K in 2024 and €38.7K in 2023, while profit margin recovered to 6.1% after 4.8% in 2024. The business generated strong returns in 2025, with ROE at 41.0% and ROA at 26.6%, supported by an asset turnover of 4.33x. At the same time, the balance sheet became smaller: total assets decreased from €361.0K in 2023 to €228.3K in 2025, and equity declined from €271.7K to €148.3K. Liabilities remained moderate at €83.1K in 2025, with a debt-to-equity ratio of 0.56 and an equity ratio of 65.0%. Revenue per employee reached €247.2K, indicating solid productivity.